Lai Wang Sells 1,367 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 1,367 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $269.38, for a total value of $368,242.46. Following the completion of the sale, the insider directly owned 40 shares in the company, valued at $10,775.20. This represents a 97.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

Shares of ONC traded down $4.56 during midday trading on Wednesday, reaching $263.61. The stock had a trading volume of 291,079 shares, compared to its average volume of 255,249. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The firm’s 50 day moving average price is $301.03 and its 200-day moving average price is $315.60. The company has a market capitalization of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. On average, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Mariner LLC raised its position in BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after buying an additional 32 shares during the period. Signaturefd LLC raised its position in BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after buying an additional 33 shares during the period. Farther Finance Advisors LLC raised its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after buying an additional 39 shares during the period. CWM LLC raised its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the period. Finally, Benjamin Edwards Inc. raised its position in BeOne Medicines by 8.0% during the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after buying an additional 51 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ONC has been the topic of a number of research reports. Truist Financial reissued a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research note on Thursday, May 7th. Wells Fargo & Company initiated coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their target price on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Barclays upped their price target on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.